Diagnostic assay to predict cardiovascular risk
AssigneesGenway Biotech Inc., Emory University, MedStar Health Research Institute, Inc.
InventorsSergey Sikora, Stephen Epstein, Arshed A. Quyyumi
Life of this patent
Estimating the term…
Abstract
This invention relates to the area of cardiovascular disorders and specifically relates to methods of diagnostic tests using a combination of markers to predict an individual's risk for developing coronary artery disease (CAD) and related diseases, such as angina pectoris and peripheral vascular disease and, more particularly, to determine an individual's risk of myocardial infarction, death, and stroke. Exemplary biomarkers include C-reactive protein (CRP), fibrin degradation products (FDPs), Heat Shock Protein 70 (HSP70), and/or anti-CMV antibody.
Claims30
A method of determining risk of an adverse cardiovascular outcome in a subject, the method comprising:
- measuring the level of each of a plurality of biomarkers in a test biological sample obtained from the subject, wherein:
- the plurality of biomarkers comprises (i) a fibrin and fibrinogen degradation product (FDP) marker, wherein the FDP marker includes a mixture of at least two fibrin and fibrinogen degradation products (FDPs) selected from the group consisting of fragment D, fragment E, D-dimer, fragment X, fragment Y, and an initial plasmin digest product (IPDP), and (ii) at least one inflammation biomarker, autoimmune disease biomarker, or cellular stress biomarker;
- and
- the levels of the plurality of biomarkers indicate a risk of an adverse cardiovascular outcome in the subject.
A method of determining risk of an adverse cardiovascular outcome in a subject, the method comprising:
- contacting a test biological sample from the subject with a panel of agents that specifically bind to a plurality of biomarkers, thereby measuring levels of the plurality of biomarkers, wherein:
- the plurality of biomarkers includes a fibrin and fibrinogen degradation product (FDP) marker and at least one inflammation biomarker, autoimmune disease biomarker, or cellular stress biomarker;
- the panel of agents includes an agent or agents that specifically binds or bind to at least two fibrin and fibrinogen degradation products (FDPs) selected from the group consisting of fragment D, fragment E, D-dimer, fragment X, fragment Y, and an initial plasmin digest product (IPDP);
- and
- the levels so measured indicate a risk of an adverse cardiovascular outcome in the subject.
3-5. (canceled)
(canceled)
9-10. (canceled)
12-17. (canceled)
A method of determining risk of an adverse cardiovascular outcome in a subject, the method comprising:
- comparing the level of each of a plurality of biomarkers in a test biological sample from the subject to a control level of the respective biomarker, wherein:
- the plurality of biomarkers comprises (i) a fibrin and fibrinogen degradation product (FDP) marker, wherein the FDP marker includes a mixture of at least two fibrin and fibrinogen degradation products (FDPs) selected from the group consisting of fragment D, fragment E, D-dimer, fragment X, fragment Y, and an initial plasmin digest product (IPDP), and (ii) at least one inflammation or autoimmune disease biomarker;
- and
- an increase in the levels of the plurality of biomarkers in the test sample compared to the control levels, indicates a risk of an adverse cardiovascular outcome in the subject.
23-24. (canceled)
26-27. (canceled)
(canceled)
31-33. (canceled)
39-43. (canceled)
(canceled)
Dependencies are inferred from the claim text.